Biotechnology · San Diego, California, United States
$5.62
-1.06% (-$0.06)2026-08-24
Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$17K, 4 sales vs 9 buys)
Revenue$0
Net Income-$10.2M
EPS$-1.52
Market Cap$63.8M
Price Performance
Historical data including institutional events
Company Profile
K
Kristin Yarema
CEO & Executive Director
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
